Pfizer, Inc.

PFE

US7170811035

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 02:17:17 2024-07-10 pm EDT			5-day change	1st Jan Change
28.22 ^USD	+1.79%		+2.04%	-1.82%

04:15pm	Pfizer: collaboration agreement with Evotec in France	CF
03:36pm	Barclays Adjusts Pfizer's Price Target to $30 From $28	MT

PFIZER INC : JP Morgan gives a Neutral rating

July 10, 2024 at 02:32 am EDT

In a research note published by Chris Schott, JP Morgan gives a Neutral rating to the stock. The target price is unchanged at USD 30.

Latest news about Pfizer, Inc.

Pfizer: collaboration agreement with Evotec in France	10:15am	CF
Barclays Adjusts Pfizer's Price Target to $30 From $28	09:36am	MT
Sector Update: Health Care Stocks Steady Premarket Wednesday	09:14am	MT
Evotec, Pfizer Enter Research Collaboration on Metabolic, Infectious Diseases	03:38am	MT
Evotec, Pfizer Team Up for Early Drug Discovery for Metabolic, infectious Diseases	03:30am	MT
Evotec with new recovery attempt - cooperation with Pfizer	03:18am	DP
PFIZER INC : JP Morgan gives a Neutral rating	02:32am	ZD
Evotec and Pfizer Collaborate to Advance Drug Discovery in France	01:50am	CI
Pfizer: succession open for scientific director	Jul. 09	CF
Pfizer Begins External Search for Chief Scientific Officer	Jul. 09	MT
Pfizer Chief Scientific Officer Mikael Dolsten Leaving	Jul. 09	DJ
Pfizer's longtime science chief Mikael Dolsten to step down	Jul. 09	RE
Pfizer Chief Scientific Officer Mikael Dolsten to step down	Jul. 09	RE
Pfizer Inc. Announces Resignation of Mikael Dolsten as Chief Scientific Officer and President	Jul. 09	CI
Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births	Jul. 08	RE
Rhythm Pharmaceuticals, Inc. Announces Appointment of Alastair Garfield, as Chief Scientific Officer	Jul. 08	CI
Novo Nordisk Reprimanded in UK Over Undisclosed Payments; Novartis, Pfizer Found in Breach of Industry Code	Jul. 05	MT
UK Pharmaceutical Trade Group Slams Novartis, Three Others for Breaches	Jul. 05	MT
Pfizer: former State Street CEO joins board	Jul. 05	CF
GlaxoSmithkline Pharmaceuticals Limited Announces Change in Management	Jul. 05	CI
PFIZER INC : Berenberg gives a Neutral rating	Jul. 03	ZD
Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits	Jul. 03	MT
Top Midday Stories: Tesla, GM Report Vehicle Deliveries; Biden, Sanders Say Novo Nordisk, Eli Lilly Charge 'Unconscionably' High Prices; Warner Bros. Interested in Deal With Paramount	Jul. 02	MT
Moderna, Pfizer-BioNTech COVID-19 Vaccine Patent Legal Battle Gets Mixed UK Ruling	Jul. 02	MT
Pfizer-BioNTech, Moderna Set to Appeal Mixed UK Ruling in COVID-19 Vaccine Patent Case	Jul. 02	MT

Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).

Sector

Pharmaceuticals

Calendar

2024-07-25 - Détachement de

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Pfizer, Inc: A cycle for nothing?

December 14, 2023 at 10:58 am EST

Albert Bourla, Pfizer CEO (full interview): mRNA, acquisitions, weight-loss drugs

October 31, 2023 at 04:50 pm EDT

More Strategies

Ratings for Pfizer, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

27.72 USD

Average target price

32.01 USD

Spread / Average Target

+15.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PFIZER, INC.	-1.72%	157B
ELI LILLY AND COMPANY	+61.52%	840B
NOVO NORDISK A/S	+39.84%	621B
JOHNSON & JOHNSON	-5.16%	354B
MERCK & CO., INC.	+16.85%	319B
ABBVIE INC.	+7.92%	297B
ASTRAZENECA PLC	+13.94%	237B
NOVARTIS AG	+15.82%	221B
ROCHE HOLDING AG	+1.84%	220B
AMGEN INC.	+11.48%	169B

Other Pharmaceuticals

Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

PFIZER INC : JP Morgan gives a Neutral rating

Latest news about Pfizer, Inc.

Chart Pfizer, Inc.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Pfizer, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals